12 assets in Acute Myeloid Leukemia With BCR-ABL1

Therapeutic assets addressing Acute Myeloid Leukemia With BCR-ABL1, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Blinatumomab Acute Myeloid Leukemia With BCR-ABL1	M.D. Anderson Cancer Center	P2	B (60)
Cytarabine Acute Myeloid Leukemia With BCR-ABL1	M.D. Anderson Cancer Center	P2	B (60)
(+)-Vincristine Acute Myeloid Leukemia With BCR-ABL1	M.D. Anderson Cancer Center	P2	B (60)
Methotrexate Acute Myeloid Leukemia With BCR-ABL1	M.D. Anderson Cancer Center	P2	B (56)
Cyclophosphamide Acute Myeloid Leukemia With BCR-ABL1	M.D. Anderson Cancer Center	P2	CCC (53)
Nivestim Acute Myeloid Leukemia With BCR-ABL1	M.D. Anderson Cancer Center	P2	CCC (53)
Pegfilgrastim Acute Myeloid Leukemia With BCR-ABL1	M.D. Anderson Cancer Center	P2	CCC (53)
Ponatinib Acute Myeloid Leukemia With BCR-ABL1	M.D. Anderson Cancer Center	P2	CCC (53)
Rituximab Acute Myeloid Leukemia With BCR-ABL1	M.D. Anderson Cancer Center	P2	CCC (53)
Decitabine Acute Myeloid Leukemia With BCR-ABL1	M.D. Anderson Cancer Center	P1	CC (43)
Lisaftoclax Acute Myeloid Leukemia With BCR-ABL1	M.D. Anderson Cancer Center	P1	CC (43)
Olverembatinib Acute Myeloid Leukemia With BCR-ABL1	M.D. Anderson Cancer Center	P1	CC (43)